IP Verse

Syringe - EP2869813

The patent EP2869813 was granted to Novartis on Nov 21, 2018. The application was originally filed on Jan 25, 2013 under application number EP13701276A. The patent is currently recorded with a legal status of "Revoked".

EP2869813

NOVARTIS
Application Number
EP13701276A
Filing Date
Jan 25, 2013
Status
Revoked
Jul 29, 2022
Grant Date
Nov 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DILGAug 21, 2019KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBADMISSIBLE
HOFFMANN EITLEAug 21, 2019HOFFMANN EITLEADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTDE102008005938
INTERNATIONAL-SEARCH-REPORTUS2006293270
INTERNATIONAL-SEARCH-REPORTUS2011257601
INTERNATIONAL-SEARCH-REPORTWO2007035621
OPPOSITIONEP2869813
OPPOSITIONUS4184593
OPPOSITIONUSD430015S
OPPOSITIONWO2011006877
OPPOSITIONWO2014005728
OPPOSITIONWO9744068
OTHERWO9744068

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Sumit Majumdar ET AL, "Evaluation of the effect of syringe surfaces on protein formulations", Journal of Pharmaceutical Sciences, (20110701), vol. 100, no. 7, doi:10.1002/jps.22515, ISSN 0022-3549, pages 2563 - 2573, XP055059280
OPPOSITION- "3.2.8 Sterile Einmalspritzen aus Kunststoff", Ph.Eur. 7. Ausgabe Grundwerk, (20110000), pages 522 - 523, XP055642513-
OPPOSITION- "67 273 Lucentis® 10mg/ml Injektionlösung", Marion Dassinger et al.,, Rote Liste® 2009, Frankfurt/Main, Rote Liste® Service GmbH, (20090000), XP055638334-
OPPOSITION- "789- Particulate Matter in Ophtalmic Solutions", U. S. Pharmacopeia, URL: http://ftp.uspbpep.com/v29240/usp29nf24s0_c789.html-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTISâ„¢ (ranibizumab injection)", Genentech, Inc.,, (2006), pages 1 - 7, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf, XP055642530-
OPPOSITION- Anonymous, "Particle Counting in Injectable Solutions 2007 Updates", Particle Measuring Systems, Inc., (20070000), page 6pp, XP055642519-
OPPOSITION- Anonymous, "Prefilled syringes- Part 6 : Plastic barrels for injectables", International standard : ISO 11040-6: 2012 (E), (20120401), pages ii-iv, 1 - 10, XP055642502-
OPPOSITION- Anonymous, "PRODUCT INFORMATION EYLEA® aflibercept (rch)", Australian Register of Therapeutic Goods, (20120307), pages 1 - 18, XP055642472-
OPPOSITION- Anonymous, "Sterile Einmalspritzen für medizinische Zwecke Teil 1: Spritzen zum manuellen Gebrauch", Deutsche Norm DIN EN ISO 7886-1, (199710), pages 1 - 19, XP055493706-
OPPOSITION- Anonymous, "The United States Pharmacopeia USP 31. National Formulary NF 26", Physical Tests/ (789) Particulate Matter in Ophthalmic Solutions, (20080501), vol. 1, pages 2p, 313 - 314, XP055642492-
OPPOSITION- Anonymous, "Vorgefüllte Spritzen Teil 4: Spritzenzylinder aus Glas für Injektionspräparate", Deutsche Norm Din ISO 11040-4, (199608), pages 1 - 5, XP055642494-
OPPOSITION- "between", Cambridge dictionary, URL: https://dictionary.cambridge.org/dictionary/english/between-
OPPOSITION- "between", Oxford dictionary, URL: https://en.oxforddictionaries.com/definition/between-
OPPOSITION- Bruno REUTER, Claudia Petersen, "Syringe Siliconization Trends, methods, analysis procedures", TechnoPharm, (20120000), vol. 2, no. 4, pages 238 - 244, XP002725465-
OPPOSITION- Cliff MINTZ, "Prefilled Syringes: The Next ''Big Thing"", Bioprocess Online, (20120830), XP002788671-
OPPOSITION- CLUNAS et al., "RANIBIZUMAB PRE-FILLED SYRINGE: RECENTLY APPROVED INNOVATION IN THE EUROPEAN UNION WITH THE POTENTIAL TO REDUCE INFECTION RISK, IMPROVE DOSE ACCURACY, AND ENHANCE EFFICIENT TREATMENT ADMINISTRATION", 5th World Congress on Controversies in Ophthalmology (COPHY), (20140320), URL: http://comtecmed.com/COPHY/2014/Uploads/Editor/Group%20A/17.pdf, XP055638316-
OPPOSITION- Frank BÖTTGER, "More than Filling. New Developments in Siliconization and Silicone Layer Analytics", Bio Production Forum - Fill and Finish for Biopharmaceuticals, (20100615), pages 1 - 43, XP055642524-
OPPOSITION- Markus Lankers, "The Relationship Between Silicone Layer Thickness, Free Silicone Oil and Protein Aggregation in Prefilled Syringes", AAPS National Biotechnology Conference, (2010), pages 1 - 46, XP055186273-
OPPOSITION- "Product Information - for publication (Replacement)", Therapeutic Goods Administration, (20120606), URL: https://www.ebs.tga.gov.au/ebs/picmi/picmi.nsf/0/CA2576320083AA90CA2579BC001671F3-
OPPOSITION- Regeneron Pharmaceuticals, Inc.,, "Aflibercept injection for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD)", Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package, pages 1 - 70-
OPPOSITION- Roche, "FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema", European Pharmaceutical Review, (20120813), pages 1 - 7, URL: https:/ /www.european pharmaceuticalreview.com/news/14197/fda-approves-lucentis-ranibizumab-injection-for-treatment-of-diabetic-macular-edema/, XP055544843-
OPPOSITION- SCHOENKNECHT T P; ET AL, "REQUIREMENTS ON PRE-FILLABLE GLASS SYRINGES", AAPS National Biotechnology Conference, (20070000), XP003035654-
OPPOSITION- FUNKE et al., "Analysis of thin baked-on silicone layers by FTIR and 3D- Laser Scanning Microscopy", European Journal of Pharmaceutics and Biopharmaceutics, (20150000), vol. 96, pages 304 - 313, XP055642550
OPPOSITION- BAKRI et al., "Intravitreal Silicone Oil Droplets After Intravitreal Drug Injections", Retina, (20080000), vol. 28, no. 7, pages 996 - 1001, XP055186525
OPPOSITION- BAKRI et al., "Intravitreal silicone oil droplets after intravitreal drug injections", Retina, (20080700), vol. 28, no. 7, pages 996 - 1001, XP055186525
OPPOSITION- BADKAR et al., "Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches", AAPS PharmSciTech, (20110600), vol. 12, no. 2, pages 564 - 572, XP019925550
OPPOSITION- CHAN et al., "SYRINGE SILICONIZATION PROCESS INVESTIGATION AND OPTIMIZATION", PDA J. Pharm. Sci. And Tech., (20120000), vol. 66, pages 136 - 150, XP003035655
OTHER- CARSTEN H. ET AL, "STEPS FOR A SAFE INTRAVITREAL INJECTION TECHNIQUE", RETINAL PHYSICIAN, (20090701), pages 1 - 5, XP003035660-
OTHER- LANKERS M., "THE RELATIONSHIP BETWEEN SILICONE LAYER THICKNESS, FREE SILICONE OIL AND PROTEINAGGREGATION", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, (2010), pages 1 - 46, XP055186273-
OTHER- SCHOENKNECHT T.P. ET AL, "REQUIREMENTA ON PRE-FILLABLE GLASS SYRINGES", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, (20070627), page 1, XP003035654-
OTHER- SUMIT MAJUMDAR ET AL, "EVALUATION OF THE EFFECT OF SYRINGE SURFACES ON PROTEIN FORMULATIONS", JOURNAL OF PHARMACEUTICAL SCIENCES, (201107), vol. 100, no. 7, pages 2563 - 2573, XP055059280
OTHER- SOPHIE J. ET AL, "INTRAVITREAL SILICONE OIL DROPLETS AFTER INTRAVITREAL DRUG INJECTIONS", THE JOURNAL OF RETINAL AND VITREOUS DISEASES, (20080101), pages 996 - 1001, XP055186525
OTHER- CHAN E. ET AL, "SYRINGE SILICONIZATION PROCESS INVESTIGATION AND OPTIMIZATION", PDA JOURNAL PF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, (2012), vol. 66, pages 136 - 150, XP003035655

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents